Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;28(Suppl 2):115S–130S. doi: 10.1111/j.1365-2125.1989.tb03587.x

Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE)

D W Cushman, F L Wang, W C Fung, G J Grover, C M Harvey, R J Scalese, S L Mitch, J M Deforrest
PMCID: PMC1379851  PMID: 2557876

Abstract

1 Seven drugs (captopril, zofenopril, enalapril, ramipril, lisinopril, fosinopril, and SQ 29,852) were compared in vitro in homogenates of aorta, brain, heart, lung, and kidney and in sera of spontaneously hypertensive rats (SHR) both with respect to potencies of their active moieties as inhibitors of angiotensin-converting enzyme (ACE), and, where applicable, rates of hydrolysis of their prodrug ester functions.

2 In ex vivo dose-response and time-course studies, the inhibitory effects of the seven drugs on tissue ACEs and their relative distributions to SHR tissues were compared following oral administration.

3 The relative potencies of the inhibitory moieties of the drugs (in parentheses) and the normalized `equiactive' oral doses employed for time-course studies were: SQ 29,852 (1.0), 100 mg kg-1; captopril (3.5), 30 mg kg-1; enalapril (12), 20 mg kg-1; fosinopril (13), 25 mg kg-1; zofenopril (20), 10 mg kg-1; lisinopril (24), 10 mg kg-1; and ramipril (51), 5 mg kg-1.

4 Following oral administration of the drugs to SHR, the degree and duration of ACE inhibition in aorta and lung correlated with the antihypertensive actions, with ramipril, lisinopril, and zofenopril producing effects of the greatest magnitude and duration.

5 Ramipril and enalapril did not inhibit brain ACE ex vivo; captopril and zofenopril had modest but short-lasting effects; and fosinopril, lisinopril, and SQ 29,852 had long-lasting inhibitory actions, which, with the latter two, were delayed in onset.

6 All of the drugs produced significant inhibition of kidney ACE, with ramipril and fosinopril having somewhat weaker effects, perhaps due to biliary routes of excretion.

7 Captopril, fosinopril, and particularly zofenopril inhibited cardiac ACE ex vivo with degrees and durations that were marked compared with those of the other drugs; preliminary studies with isolated hearts suggest a possible relationship between inhibition of cardiac ACE and preservation of cardiac function subsequent to ischaemia.

Keywords: ACE inhibitors, tissue distribution, spontaneously hypertensive rats

Full text

PDF
115S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armayor G. M., Lopez L. M. Lisinopril: a new angiotensin-converting enzyme inhibitor. Drug Intell Clin Pharm. 1988 May;22(5):365–372. doi: 10.1177/106002808802200501. [DOI] [PubMed] [Google Scholar]
  2. Bagchi D., Prasad R., Das D. K. Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Commun. 1989 Jan 16;158(1):52–57. doi: 10.1016/s0006-291x(89)80175-5. [DOI] [PubMed] [Google Scholar]
  3. Ball S. G., Robertson J. I. Clinical pharmacology of ramipril. Am J Cardiol. 1987 Apr 24;59(10):23D–27D. doi: 10.1016/0002-9149(87)90048-8. [DOI] [PubMed] [Google Scholar]
  4. Becker R. A., Schölkens B. Ramipril: review of pharmacology. Am J Cardiol. 1987 Apr 24;59(10):3D–11D. doi: 10.1016/0002-9149(87)90045-2. [DOI] [PubMed] [Google Scholar]
  5. Belz G. G., Kirch W., Kleinbloesem C. H. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet. 1988 Nov;15(5):295–318. doi: 10.2165/00003088-198815050-00003. [DOI] [PubMed] [Google Scholar]
  6. Borek M., Charlap S., Frishman W. Enalapril: a long-acting angiotensin-converting enzyme inhibitor. Pharmacotherapy. 1987;7(5):133–148. doi: 10.1002/j.1875-9114.1987.tb04039.x. [DOI] [PubMed] [Google Scholar]
  7. Brunner H. R., Waeber B., Nussberger J. Pharmacology of converting enzyme inhibitors. Clin Exp Hypertens A. 1987;9(2-3):275–288. doi: 10.3109/10641968709164187. [DOI] [PubMed] [Google Scholar]
  8. Cheung H. S., Wang F. L., Ondetti M. A., Sabo E. F., Cushman D. W. Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. J Biol Chem. 1980 Jan 25;255(2):401–407. [PubMed] [Google Scholar]
  9. Chevillard C., Brown N. L., Mathieu M. N., Laliberté F., Worcel M. Differential effects of oral trandolapril and enalapril on rat tissue angiotensin-converting enzyme. Eur J Pharmacol. 1988 Feb 16;147(1):23–28. doi: 10.1016/0014-2999(88)90629-2. [DOI] [PubMed] [Google Scholar]
  10. Cohen M. L., Kurz K. D. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther. 1982 Jan;220(1):63–69. [PubMed] [Google Scholar]
  11. Cushman D. W., Ondetti M. A., Gordon E. M., Natarajan S., Karanewsky D. S., Krapcho J., Petrillo E. W., Jr Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J Cardiovasc Pharmacol. 1987;10 (Suppl 7):S17–S30. doi: 10.1097/00005344-198706107-00004. [DOI] [PubMed] [Google Scholar]
  12. Dzau V. J. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987 Jan 23;59(2):59A–65A. doi: 10.1016/0002-9149(87)90178-0. [DOI] [PubMed] [Google Scholar]
  13. Ertl G., Kloner R. A., Alexander R. W., Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation. 1982 Jan;65(1):40–48. doi: 10.1161/01.cir.65.1.40. [DOI] [PubMed] [Google Scholar]
  14. Gay R. J., McComb R. B., Bowers G. N., Jr Optimum reaction conditions for human lactate dehydrogenase isoenzymes as they affect total lactate dehydrogenase activity. Clin Chem. 1968 Aug;14(8):740–753. [PubMed] [Google Scholar]
  15. Inada Y., Terashita Z., Imura Y., Tanabe M., Nishikawa K., Kikuchi S. Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound. Jpn J Pharmacol. 1986 Sep;42(1):99–108. doi: 10.1254/jjp.42.99. [DOI] [PubMed] [Google Scholar]
  16. Jackson B., Cubela R. B., Johnston C. I. Inhibition of tissue angiotensin converting enzyme by perindopril: in vivo assessment in the rat using radioinhibitor binding displacement. J Pharmacol Exp Ther. 1988 Jun;245(3):950–955. [PubMed] [Google Scholar]
  17. Jackson B., Cubela R., Sakaguchi K., Johnston C. I. Pharmacokinetics of angiotensin converting enzyme inhibition in tissues following oral lisinopril: studies in the rat using quantitative radioinhibitor binding. Clin Exp Pharmacol Physiol. 1987 Apr;14(4):343–347. doi: 10.1111/j.1440-1681.1987.tb00981.x. [DOI] [PubMed] [Google Scholar]
  18. Karanewsky D. S., Badia M. C., Cushman D. W., DeForrest J. M., Dejneka T., Loots M. J., Perri M. G., Petrillo E. W., Jr, Powell J. R. (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE. J Med Chem. 1988 Jan;31(1):204–212. doi: 10.1021/jm00396a033. [DOI] [PubMed] [Google Scholar]
  19. Kostis J. B. Angiotensin converting enzyme inhibitors. I. Pharmacology. Am Heart J. 1988 Dec;116(6 Pt 1):1580–1591. doi: 10.1016/0002-8703(88)90747-8. [DOI] [PubMed] [Google Scholar]
  20. Kostis J. B. Angiotensin converting enzyme inhibitors. II. Clinical use. Am Heart J. 1988 Dec;116(6 Pt 1):1591–1605. doi: 10.1016/0002-8703(88)90748-x. [DOI] [PubMed] [Google Scholar]
  21. Kostis J. B. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. Am J Hypertens. 1989 Jan;2(1):57–64. doi: 10.1093/ajh/2.1.57. [DOI] [PubMed] [Google Scholar]
  22. Krapcho J., Turk C., Cushman D. W., Powell J. R., DeForrest J. M., Spitzmiller E. R., Karanewsky D. S., Duggan M., Rovnyak G., Schwartz J. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J Med Chem. 1988 Jun;31(6):1148–1160. doi: 10.1021/jm00401a014. [DOI] [PubMed] [Google Scholar]
  23. Leenen F. H., de Jong W. A solid silver clip for induction of predictable levels of renal hypertension in the rat. J Appl Physiol. 1971 Jul;31(1):142–144. doi: 10.1152/jappl.1971.31.1.142. [DOI] [PubMed] [Google Scholar]
  24. Lindpaintner K., Wilhelm M. J., Jin M., Unger T., Lang R. E., Schoelkens B. A., Ganten D. Tissue renin-angiotensin systems: focus on the heart. J Hypertens Suppl. 1987 Jul;5(2):S33–S38. doi: 10.1097/00004872-198707002-00007. [DOI] [PubMed] [Google Scholar]
  25. Linz W., Schölkens B. A., Han Y. F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8 (Suppl 10):S91–S99. doi: 10.1097/00005344-198600101-00017. [DOI] [PubMed] [Google Scholar]
  26. Miyazaki M., Okamura T., Okunishi H., Toda N. Possible role of vascular angiotensin converting enzyme in the genesis of hypertension. Clin Exp Hypertens A. 1987;9(2-3):435–440. doi: 10.3109/10641968709164210. [DOI] [PubMed] [Google Scholar]
  27. Mizuno K., Nakamaru M., Higashimori K., Inagami T. Local generation and release of angiotensin II in peripheral vascular tissue. Hypertension. 1988 Mar;11(3):223–229. doi: 10.1161/01.hyp.11.3.223. [DOI] [PubMed] [Google Scholar]
  28. Nakamura Y., Nakamura K., Matsukura T., Nakamura K. Vascular angiotensin converting enzyme activity in spontaneously hypertensive rats and its inhibition with cilazapril. J Hypertens. 1988 Feb;6(2):105–110. [PubMed] [Google Scholar]
  29. Norman J. A., Lehmann M., Goodman F. R., Barclay B. W., Zimmerman M. B. Central and peripheral inhibition of angiotensin converting enzyme (ACE) in the SHR: correlation with the antihypertensive activity of ACE inhibitors. Clin Exp Hypertens A. 1987;9(2-3):461–468. doi: 10.3109/10641968709164213. [DOI] [PubMed] [Google Scholar]
  30. Packer M., Lee W. H., Yushak M., Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986 Oct 2;315(14):847–853. doi: 10.1056/NEJM198610023151402. [DOI] [PubMed] [Google Scholar]
  31. Pfeffer J. M., Pfeffer M. A., Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985 Jul;57(1):84–95. doi: 10.1161/01.res.57.1.84. [DOI] [PubMed] [Google Scholar]
  32. Pfeffer M. A., Pfeffer J. M., Steinberg C., Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985 Aug;72(2):406–412. doi: 10.1161/01.cir.72.2.406. [DOI] [PubMed] [Google Scholar]
  33. Piquilloud Y., Reinharz A., Roth M. Studies on the angiotensin converting enzyme with different substrates. Biochim Biophys Acta. 1970 Apr 22;206(1):136–142. doi: 10.1016/0005-2744(70)90090-2. [DOI] [PubMed] [Google Scholar]
  34. Rochette L., Ribuot C., Belichard P., Bril A., Devissaguet M. Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat. Clin Exp Hypertens A. 1987;9(2-3):365–368. doi: 10.3109/10641968709164198. [DOI] [PubMed] [Google Scholar]
  35. Sakaguchi K., Chai S. Y., Jackson B., Johnston C. I., Mendelsohn F. A. Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography. Hypertension. 1988 Mar;11(3):230–238. doi: 10.1161/01.hyp.11.3.230. [DOI] [PubMed] [Google Scholar]
  36. Schölkens B. A., Linz W., Han Y. F. Heart and vascular wall as targets for tissue converting enzyme inhibition. Clin Exp Hypertens A. 1987;9(2-3):427–433. doi: 10.3109/10641968709164209. [DOI] [PubMed] [Google Scholar]
  37. Schölkens B. A., Xiang J. Z., Tilly H. Influence of the converting enzyme inhibitors Hoe 498, enalapril and captopril on vascular reactivity of isolated arterial preparations. Clin Exp Hypertens A. 1984;6(10-11):1807–1813. doi: 10.3109/10641968409046083. [DOI] [PubMed] [Google Scholar]
  38. Singhvi S. M., Duchin K. L., Morrison R. A., Willard D. A., Everett D. W., Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 1988 Jan;25(1):9–15. doi: 10.1111/j.1365-2125.1988.tb03275.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sullivan P. A., Dineen M., Cervenka J., O'Connor D. T. Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension. Am J Hypertens. 1988 Jul;1(3 Pt 3):280S–283S. doi: 10.1093/ajh/1.3.280s. [DOI] [PubMed] [Google Scholar]
  40. Unger T., Ganten D., Lang R. E., Schölkens B. A. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):872–880. doi: 10.1097/00005344-198409000-00021. [DOI] [PubMed] [Google Scholar]
  41. Unger T., Ganten D., Lang R. E., Schölkens B. A. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1985 Jan-Feb;7(1):36–41. doi: 10.1097/00005344-198501000-00007. [DOI] [PubMed] [Google Scholar]
  42. Unger T., Ganten D., Lang R. E. Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol. 1986;8 (Suppl 10):S75–S81. doi: 10.1097/00005344-198600101-00015. [DOI] [PubMed] [Google Scholar]
  43. Unger T., Moursi M., Ganten D., Hermann K., Lang R. E. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498). J Cardiovasc Pharmacol. 1986 Mar-Apr;8(2):276–285. doi: 10.1097/00005344-198603000-00009. [DOI] [PubMed] [Google Scholar]
  44. Velletri P., Bean B. L. The effects of captopril on rat aortic angiotensin-converting enzyme. J Cardiovasc Pharmacol. 1982 Mar-Apr;4(2):315–325. doi: 10.1097/00005344-198203000-00022. [DOI] [PubMed] [Google Scholar]
  45. Williams G. H. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med. 1988 Dec 8;319(23):1517–1525. doi: 10.1056/NEJM198812083192305. [DOI] [PubMed] [Google Scholar]
  46. Wyvratt M. J. Evolution of angiotensin-converting enzyme inhibitors. Clin Physiol Biochem. 1988;6(3-4):217–229. [PubMed] [Google Scholar]
  47. Wyvratt M. J., Patchett A. A. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med Res Rev. 1985 Oct-Dec;5(4):483–531. doi: 10.1002/med.2610050405. [DOI] [PubMed] [Google Scholar]
  48. Xiang J. Z., Linz W., Becker H., Ganten D., Lang R. E., Schölkens B., Unger T. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol. 1985 Jul 17;113(2):215–223. doi: 10.1016/0014-2999(85)90738-1. [DOI] [PubMed] [Google Scholar]
  49. Zimmerman M. B., Barclay B. W., Lehmann M., Norman J. A. Effects of chronic administration of angiotensin converting enzyme (ACE) inhibitors on blood pressure and tissue ACE activity in the SHR. Clin Exp Hypertens A. 1987;9(2-3):473–476. doi: 10.3109/10641968709164215. [DOI] [PubMed] [Google Scholar]
  50. van Gilst W. H., de Graeff P. A., Wesseling H., de Langen C. D. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):722–728. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES